- Home
- ECBK vs NYXH Comparison
ECBK vs NYXH Comparison
Compare ECBK & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ECBK | NYXH |
|---|---|---|
| Founded | 1919 | 2009 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 176.0M | 161.9M |
| IPO Year | 2022 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ECBK | NYXH |
|---|---|---|
| Price | $20.40 | $1.40 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $9.33 |
| AVG Volume (30 Days) | 5.6K | ★ 187.2K |
| Earning Date | 05-12-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 95.83 | N/A |
| EPS | ★ 0.38 | N/A |
| Revenue | ★ $598,000.00 | N/A |
| Revenue This Year | N/A | $213.98 |
| Revenue Next Year | N/A | $126.25 |
| P/E Ratio | $52.39 | ★ N/A |
| Revenue Growth | ★ 3.64 | N/A |
| 52 Week Low | $14.83 | $1.26 |
| 52 Week High | $20.76 | $8.59 |
Technical Indicators
Market Signals| Indicator | ECBK | NYXH |
|---|---|---|
| Relative Strength Index (RSI) | 55.27 | 30.65 |
| Support Level | $17.76 | $1.26 |
| Resistance Level | $20.76 | $1.70 |
| Average True Range (ATR) | 0.34 | 0.08 |
| MACD | -0.07 | 0.01 |
| Stochastic Oscillator | 57.93 | 10.84 |
Price Performance
Historical ComparisonAbout ECBK ECB Bancorp Inc.
ECB Bancorp Inc operates as a bank holding company. The firm, through its subsidiary, engages in business consisting of taking deposits from the general public and investing those deposits, together with funds generated from operations, in one- to four-family residential real estate loans, commercial real estate, multifamily real estate loans, construction and land loans, and home equity lines of credit.
About NYXH Nyxoah SA
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.